RIKEN Center for Life Science Technologies

Topics

  • Research

    Latest publications from CLST.
     
  • News

    Awards, agreements, and other news.
  • Events

    Upcoming and past events including seminars, symposiums, open days.

For Public

To let you know about our research, this area contains 4 types of information about CLST; “Article”, “Videos”, “Event” and “Study”.
At “Article”, you can read articles on interviews and lectures, and you can enjoy the videos about CLST at “Videos”. If you want to meet and talk directly with the researcher, “Visit” give you some information of such events. You can find more difficult contents to know about our research deeply at “Study”.
  • Article
  • Event
  • Videos
  • Study

Labs & Technologies

Cellular Function Conversion Technology Team

* Due to the reorganization starting as new centers in April 2018, this laboratory is now belong to the Center for Integrative Medical Sciences. As for the latest information, please see the following URL below.
> The webpage of Laboratory for Cellular Function Conversion Technology, Center for Integrative Medical Sciences

Team Leader
Harukazu Suzuki  Ph.D.

1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, JAPAN

2_6_suzuki.png

Research Area

We will develop technologies for direct cell conversion to target cell types of potential therapeutic interest, based on the integrated knowledge of the transcriptome status, the transcriptional basins, the epigenome, and the non-coding RNA, including technologies for high efficient, loci specific epigenome modification. Linked to the direct cell conversion, differentiation and safety of stem cells will be explored. We also aim at application of the transcriptional regulatory network analysis technologies to wide variety of biological sresearch.

Main Publications List

1

An atlas of human long non-coding RNAs with accurate 5' ends.

Hon CC, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJ, Gough J, Denisenko E, Schmeier S, Poulsen TM, Severin J, Lizio M, Kawaji H, Kasukawa T, Itoh M, Burroughs AM, Noma S, Djebali S, Alam T, Medvedeva YA, Testa AC15, Lipovich L, Yip CW, Abugessaisa I, Mendez M, Hasegawa A, Tang D, Lassmann T, Heutink P, Babina M, Wells CA, Kojima, Nakamura Y, Suzuki H, Daub CO, de Hoon MJ, Arner E, Hayashizaki Y, Carninci P, Forrest AR.
Nature, 543(7644), 199-204 (2017).
2

Asymmetric Regulation of Peripheral Genes by Two Transcriptional Regulatory Networks.

Li JR, Suzuki T, Nishimura H, Kishima M, Maeda S, Suzuki H.
PLoS One., 11(8), e0160459 (2016).
3

Enhanced Identification of Transcriptional Enhancers Provides Mechanistic Insights into Diseases.

Murakawa Y, Yoshihara M, Kawaji H, Nishikawa M, Zayed H, Suzuki H, Fantom Consortium, Hayashizaki Y.
Trends Genet., 32(2), 76-88 (2016).
4

A predictive computational framework for direct reprogramming between human cell types

Rackham OJ, Firas J, Fang H, Oates ME, Holmes ML, Knaupp AS,; FANTOM Consortium, Suzuki H, Nefzger CM, Daub CO, Shin JW, Petretto E, Forrest AR, Hayashizaki Y, Polo JM, Gough J.
Nat Genet, 48(3), 331-335 (2016).
5

Batf2/Irf1 Induces Inflammatory Responses in Classically Activated Macrophages, Lipopolysaccharides, and Mycobacterial Infection.

Roy S, Guler R, Parihar SP, Schmeier S, Kaczkowski B, Nishimura H, Shin JW, Negishi Y, Ozturk M, Hurdayal R, Kubosaki A, Kimura Y, de Hoon MJ, Hayashizaki Y, Brombacher F, Suzuki H.
J Immunol, 194(12), 6035-6044 (2015).
6

Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells.

Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drabløs F, Lennartsson A, Rönnerblad M, Hrydziuszko O, Vitezic M, Freeman TC, Alhendi AM, Arner P, Axton R, Baillie JK, Beckhouse A, Bodega B, Briggs J, Brombacher F, Davis M, Detmar M, Ehrlund A, Endoh M, Eslami A, Fagiolini M, Fairbairn L, Faulkner GJ, Ferrai C, Fisher ME, Forrester L, Goldowitz D, Guler R, Ha T, Hara M, Herlyn M, Ikawa T, Kai C, Kawamoto H, Khachigian LM, Klinken SP, Kojima S, Koseki H, Klein S, Mejhert N, Miyaguchi K, Mizuno Y, Morimoto M, Morris KJ, Mummery C, Nakachi Y, Ogishima S, Okada-Hatakeyama M, Okazaki Y, Orlando V, Ovchinnikov D, Passier R, Patrikakis M, Pombo A, Qin XY, Roy S, Sato H, Savvi S, Saxena A, Schwegmann A, Sugiyama D, Swoboda R, Tanaka H, Tomoiu A, Winteringham LN, Wolvetang E, Yanagi-Mizuochi C, Yoneda M, Zabierowski S, Zhang P, Abugessaisa I, Bertin N, Diehl AD, Fukuda S, Furuno M, Harshbarger J, Hasegawa A, Hori F, Ishikawa-Kato S, Ishizu Y, Itoh M, Kawashima T, Kojima M, Kondo N, Lizio M, Meehan TF, Mungall CJ, Murata M, Nishiyori-Sueki H, Sahin S, Nagao-Sato S, Severin J, de Hoon MJ, Kawai J, Kasukawa T, Lassmann T, Suzuki H, Kawaji H, Summers KM, Wells C; FANTOM Consortium, Hume DA, Forrest AR, Sandelin A, Carninci P, Hayashizaki Y.
Science, 347(6225), 1010-1014 (2015).
7

A transient disruption of fibroblastic transcriptional regulatory network facilitates trans-differentiation.

Tomaru Y, Hasegawa R, Suzuki T, Sato T, Kubosaki A, Suzuki M, Kawaji H, Forrest AR, Hayashizaki Y; FANTOM Consortium, Shin JW, Suzuki H.
Nucleic Acids Research, 42(14), 8905-8913 (2014).
8

A promoter-level mammalian expression atlas

FANTOM Consortium and the RIKEN PMI and CLST (DGT)
Nature, 507(7493), 462-470 (2014).
9

An atlas of active enhancers across human cell types and tissues

Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X, Schmidl C, Suzuki T, Ntini E, Arner E, Valen E, Li K, Schwarzfischer L, Glatz D, Raithel J, Lilje B, Rapin N, Bagger FO, Jørgensen M, Andersen PR, Bertin N, Rackham O, Burroughs AM, Baillie JK, Ishizu Y, Shimizu Y, Furuhata E, Maeda S, Negishi Y, Mungall CJ, Meehan TF, Lassmann T, Itoh M, Kawaji H, Kondo N, Kawai J, Lennartsson A, Daub CO, Heutink P, Hume DA, Jensen TH, Suzuki H, Hayashizaki Y, Müller F; FANTOM Consortium, Forrest AR, Carninci P, Rehli M, Sandelin A.
Nature, 507(7493), 455-461 (2014).
10

Capturing drug responses by quantitative promoter activity profiling.

Kajiyama K, Okada-Hatakeyama M, Hayashizaki Y, Kawaji H, Suzuki H.
CPT Pharmacometrics Syst Pharmacol, 2, e77 (2013).

>>ALL  Publications

Member  *concurrent

CLST was reorganized into three centers according to the RIKEN 4th Medium-Term Plan from April 1, 2018. For the latest information of Cellular Function Conversion Technology Team, please visit the following websites.


> The webpage of Laboratory for Cellular Function Conversion Technology, Center for Integrative Medical Sciences [http://www.ims.riken.jp/labo/65/index.html]